Pub Date : 1981-05-01DOI: 10.1016/0014-2964(81)90051-7
Hiroshi Nagasawa, Reiko Yanai
Mammary gland DNA synthesis estimated by the in vitro incorporation of [3H]thymidine in response to mammotropic hormones was compared between high and low mammary tumor strains of virgin mice (SHN and SLN). In SHN, mammary gland DNA synthesis when cultured in the medium containing insulin (I), aldosterone (A), estradiol-17β (E), progesterone, prolactin (PRL) and growth hormone (GH) showed a peak on day 2 of culture and declined thereafter. Quite the opposite was the case in SLN mammary glands. There was little strain-difference in mammary gland DNA synthesis when cultured for 6 days in the medium containing complete hormone mixture. However, DNA synthesis of SHN mammary glands cultured in the medium deficient in PRL was less than one-third of the control, whereas that of SLN glands was two-thirds of the control. Moreover, mammary gland DNA synthesis was decreased significantly by deficiency in GH or E in SHN strain only. In both strains, mammary gland DNA synthesis declined with an increasing dose of PRL when cultured in the medium containing I, A and PRL, which was associated with an activated secretory function. However, the changes were much more marked in SHN than in SLN. The results have demonstrated the higher dependency of SHN mammary glands than SLN glands upon mammotropic hormones, especially PRL. They further indicate that mammary gland potential for both growth and function is well reflected by mammary gland sensitivity to PRL.
{"title":"The In Vitro mammary gland response to mammotropic hormones in mice with different mammary tumorigenesis","authors":"Hiroshi Nagasawa, Reiko Yanai","doi":"10.1016/0014-2964(81)90051-7","DOIUrl":"10.1016/0014-2964(81)90051-7","url":null,"abstract":"<div><p>Mammary gland DNA synthesis estimated by the <em>in vitro</em> incorporation of [<sup>3</sup>H]thymidine in response to mammotropic hormones was compared between high and low mammary tumor strains of virgin mice (SHN and SLN). In SHN, mammary gland DNA synthesis when cultured in the medium containing insulin (I), aldosterone (A), estradiol-<em>17</em>β (E), progesterone, prolactin (PRL) and growth hormone (GH) showed a peak on <em>day 2</em> of culture and declined thereafter. Quite the opposite was the case in SLN mammary glands. There was little strain-difference in mammary gland DNA synthesis when cultured for <em>6 days</em> in the medium containing complete hormone mixture. However, DNA synthesis of SHN mammary glands cultured in the medium deficient in PRL was less than one-third of the control, whereas that of SLN glands was two-thirds of the control. Moreover, mammary gland DNA synthesis was decreased significantly by deficiency in GH or E in SHN strain only. In both strains, mammary gland DNA synthesis declined with an increasing dose of PRL when cultured in the medium containing I, A and PRL, which was associated with an activated secretory function. However, the changes were much more marked in SHN than in SLN. The results have demonstrated the higher dependency of SHN mammary glands than SLN glands upon mammotropic hormones, especially PRL. They further indicate that mammary gland potential for both growth and function is well reflected by mammary gland sensitivity to PRL.</p></div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 5","pages":"Pages 503-507"},"PeriodicalIF":0.0,"publicationDate":"1981-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90051-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18076974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1981-05-01DOI: 10.1016/0014-2964(81)90058-X
N.C. Gorin , R. David , J. Stachowiak , Ch. Salmon , J.C. Petit , Y. Parlier , A. Najman , G. Duhamel
Twenty-three adult patients with end stage and/or poor prognosis malignancies (6 solid tumors, 6 malignant lymphomas, 11 acute leukemias) were treated by high dose chemotherapy, with (16 patients) or without (7 patients) reinfusion of cryopreserved autologous marrow. Eighteen patients were treated by the TACC regimen (cyclophosphamide 45 mg/kg days 1–4, ARA-C 100 mg/m2 q 12 hr days 1–4, 6-thioguanine 100 mg/m2 q 12 hr days 1–4, CCNU 200 mg/m2 day 2) and others received high dose combination chemotherapy regimens designed specifically for their anticipated tumor sensitivity. Additional radiotherapy was delivered in three cases. The results were analysed for toxicity, kinetics of recovery of hematopoiesis, and anti-tumor effects. All patients receiving cryopreserved marrow engrafted successfully and none died, although severe sepsis occured in six cases. In contrast, of the seven patients who did not receive cryopreserved marrow following the TACC regimen, three died from aplasia on days 15, 24 and 33. Recovery of leukocytes (WBC) and platelets in peripheral blood occurred twice as fast in patients with cryopreserved marrow: patients with solid tumors and malignant lymphomas recovered a WBC count of 1000/mm3 and a platelet count of 50,000/mm3 on day 11, regardless of the nature of the high dose therapy. Patients with acute leukemia had slightly delayed kinetics with recovery of leukocytes (>1000/mm3) and platelets (>50,000/mm3) occurring on day 18. Five of the six patients with solid tumors had a partial response (PR) on high dose therapy. Two patients with Hodgkin's disease achieved a complete remission, but the duration of the response was short (6 and 14 weeks). All four patients with non-Hodgkin's lymphomas went into complete remission (CR) and have remained free of disease without maintenance therapy for prolonged periods. All four patients with acute leukemias who received cryopreserved marrow went into complete remission and the duration of this CR paralleled the duration of the initial CR at the beginning of which the marrow had been harvested. One patient (AML) is still in CR 32 months after high dose therapy + autologous bone marrow transplantation (ABMT). Of the seven acute leukemia patients who did not receive cryopreserved marrow, only one had a CR of very short duration (1 month), and persisting, massive leukemic infiltration was demonstrated in five. These results demonstrate that ABMT is feasible in man and that it shortens the duration of aplasia following high dose therapy by about 50%. They also suggest that high dose therapy + ABMT should be included in the management of patients with acute leukemias, non-Hodgkin's lymphomas and some selected so
{"title":"High dose chemotherapy and autologous bone marrow transplantation in acute leukemias, malignant lymphomas and solid tumors","authors":"N.C. Gorin , R. David , J. Stachowiak , Ch. Salmon , J.C. Petit , Y. Parlier , A. Najman , G. Duhamel","doi":"10.1016/0014-2964(81)90058-X","DOIUrl":"https://doi.org/10.1016/0014-2964(81)90058-X","url":null,"abstract":"<div><p>Twenty-three adult patients with end stage and/or poor prognosis malignancies (<em>6</em> solid tumors, <em>6</em> malignant lymphomas, <em>11</em> acute leukemias) were treated by high dose chemotherapy, with (<em>16</em> patients) or without (<em>7</em> patients) reinfusion of cryopreserved autologous marrow. Eighteen patients were treated by the TACC regimen (cyclophosphamide <em>45 mg/kg days 1–4</em>, ARA-C <em>100 mg/m<sup>2</sup> q 12 hr days 1–4, 6</em>-thioguanine <em>100 mg/m<sup>2</sup> q 12 hr days 1–4</em>, CCNU <em>200 mg/m<sup>2</sup> day 2</em>) and others received high dose combination chemotherapy regimens designed specifically for their anticipated tumor sensitivity. Additional radiotherapy was delivered in three cases. The results were analysed for toxicity, kinetics of recovery of hematopoiesis, and anti-tumor effects. All patients receiving cryopreserved marrow engrafted successfully and none died, although severe sepsis occured in six cases. In contrast, of the seven patients who did not receive cryopreserved marrow following the TACC regimen, three died from aplasia on days <em>15, 24</em> and <em>33</em>. Recovery of leukocytes (WBC) and platelets in peripheral blood occurred twice as fast in patients with cryopreserved marrow: patients with solid tumors and malignant lymphomas recovered a WBC count of <em>1000/mm<sup>3</sup></em> and a platelet count of <em>50,000/mm<sup>3</sup></em> on day <em>11</em>, regardless of the nature of the high dose therapy. Patients with acute leukemia had slightly delayed kinetics with recovery of leukocytes (><em>1000/mm<sup>3</sup></em>) and platelets (><em>50,000/mm<sup>3</sup></em>) occurring on day <em>18</em>. Five of the six patients with solid tumors had a partial response (PR) on high dose therapy. Two patients with Hodgkin's disease achieved a complete remission, but the duration of the response was short (<em>6</em> and <em>14 weeks</em>). All four patients with non-Hodgkin's lymphomas went into complete remission (CR) and have remained free of disease without maintenance therapy for prolonged periods. All four patients with acute leukemias who received cryopreserved marrow went into complete remission and the duration of this CR paralleled the duration of the initial CR at the beginning of which the marrow had been harvested. One patient (AML) is still in CR <em>32 months</em> after high dose therapy + autologous bone marrow transplantation (ABMT). Of the seven acute leukemia patients who did not receive cryopreserved marrow, only one had a CR of very short duration (<em>1 month</em>), and persisting, massive leukemic infiltration was demonstrated in five. These results demonstrate that ABMT is feasible in man and that it shortens the duration of aplasia following high dose therapy by about <em>50%</em>. They also suggest that high dose therapy + ABMT should be included in the management of patients with acute leukemias, non-Hodgkin's lymphomas and some selected so","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 5","pages":"Pages 557-568"},"PeriodicalIF":0.0,"publicationDate":"1981-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90058-X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72048510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1981-05-01DOI: 10.1016/0014-2964(81)90063-3
{"title":"Third university of Arizona cancer center conference on human tumor cloning","authors":"","doi":"10.1016/0014-2964(81)90063-3","DOIUrl":"https://doi.org/10.1016/0014-2964(81)90063-3","url":null,"abstract":"","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 5","pages":"Page 591"},"PeriodicalIF":0.0,"publicationDate":"1981-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90063-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72048511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1981-05-01DOI: 10.1016/0014-2964(81)90068-2
{"title":"Recent journal contents","authors":"","doi":"10.1016/0014-2964(81)90068-2","DOIUrl":"https://doi.org/10.1016/0014-2964(81)90068-2","url":null,"abstract":"","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 5","pages":"Page 594"},"PeriodicalIF":0.0,"publicationDate":"1981-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90068-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72048516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1981-05-01DOI: 10.1016/0014-2964(81)90055-4
Shalom A. Leon , Bernard Shapiro , Patricia Servi , Robert G. Parsons
Measurements of serum concentrations of DNA and the DNA-binding protein C3DP by radioimmunoassay showed that the levels of both substances tend to increase in cancer patients during active malignant disease. In most cases, the levels returned to normal during chemotherapy-induced remission; however, the changes in concentration for DNA and C3DP did not occur simultaneously, and no correlation was found between their levels. The sera of cancer patients contained a strong inhibitor of DNAse. We examined the possibility that C3DP may have such an inhibitory effect by binding to DNA and preventing the action of DNAse. The enzyme was fully active in the presence of purified C3DP, indicating that the DNAse inhibitor in cancer serum was a substance other than C3DP. Although the relationship between DNA and the DNA-binding protein remains unknown, their measurement may have diagnostic and prognostic value.
{"title":"A comparison of DNA and DNA-binding protein levels in malignant disease","authors":"Shalom A. Leon , Bernard Shapiro , Patricia Servi , Robert G. Parsons","doi":"10.1016/0014-2964(81)90055-4","DOIUrl":"10.1016/0014-2964(81)90055-4","url":null,"abstract":"<div><p>Measurements of serum concentrations of DNA and the DNA-binding protein C<em>3</em>DP by radioimmunoassay showed that the levels of both substances tend to increase in cancer patients during active malignant disease. In most cases, the levels returned to normal during chemotherapy-induced remission; however, the changes in concentration for DNA and C<em>3</em>DP did not occur simultaneously, and no correlation was found between their levels. The sera of cancer patients contained a strong inhibitor of DNAse. We examined the possibility that C<em>3</em>DP may have such an inhibitory effect by binding to DNA and preventing the action of DNAse. The enzyme was fully active in the presence of purified C<em>3</em>DP, indicating that the DNAse inhibitor in cancer serum was a substance other than C<em>3</em>DP. Although the relationship between DNA and the DNA-binding protein remains unknown, their measurement may have diagnostic and prognostic value.</p></div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 5","pages":"Pages 533-538"},"PeriodicalIF":0.0,"publicationDate":"1981-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90055-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17945278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1981-05-01DOI: 10.1016/0014-2964(81)90064-5
{"title":"First international symposium on the modulation and mediation of cancer by vitamins","authors":"","doi":"10.1016/0014-2964(81)90064-5","DOIUrl":"https://doi.org/10.1016/0014-2964(81)90064-5","url":null,"abstract":"","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 5","pages":"Page 591"},"PeriodicalIF":0.0,"publicationDate":"1981-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90064-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72048512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1981-04-01DOI: 10.1016/0014-2964(81)90245-0
H. Jung, H.-P. Beck, I. Brammer, F. Zywietz
Experiments were carried out to study the kinetics of depopulation and repopulation of the solid transplantable rhabdomyosarcoma R1H of the rat following local irradiation with a single X-ray dose of 15 Gy. Several parameters were sequentially measured over a time interval of 25 days after irradiation: The ratio of tumour to host cells was determined by flow cytometry; the numerical density of tumour cells was obtained by stereological analysis of histological slides; the clonogenic fraction of tumour cells was assayed by plating an appropriate number of tumour cells and scoring the colonies; tumour volume was assessed by measuring two tumour diameters at right angles to each other. All parameters investigated, except tumour volume, undergo drastic changes during the first 2 weeks after irradiation. From the directly measured parameters the following values and their variation with time could be derived. The number of host cells per tumour increased by a factor of 10 within the first 10 days after irradiation, probably due to infiltration by blood-borne host cells. During the same time interval, the number of tumour cells decreased by a factor of 5, whereas the total number of cells per tumour showed an increase by a factor of 4. Since the host cells are considerably smaller than the tumour cells, the cellular numerical density increased by a factor of 3, but approached the control level by Day 18 after irradiation. From the number of clonogenic and non-clonogenic tumour cells the kinetics of repopulation and depopulation was obtained. Repopulation of irradiated tumours by surviving tumour cells as well as removal of inactivated tumour cells began immediately after irradiation and proceeded with exponential kinetics. Repopulation occurred with a doubling time of 4.4 ± 0.3 days whereas inactivated tumour cells disintegrated with a halving time of 3.5 ± 0.7 days. There were no indications that proliferation of doomed cells contributed significantly to tumour growth after X-irradiation.
{"title":"Depopulation and repopulation of the R1H rhabdomyosarcoma of the rat after X-irradiation","authors":"H. Jung, H.-P. Beck, I. Brammer, F. Zywietz","doi":"10.1016/0014-2964(81)90245-0","DOIUrl":"10.1016/0014-2964(81)90245-0","url":null,"abstract":"<div><p>Experiments were carried out to study the kinetics of depopulation and repopulation of the solid transplantable rhabdomyosarcoma R<em>1</em>H of the rat following local irradiation with a single X-ray dose of <em>15 Gy</em>. Several parameters were sequentially measured over a time interval of <em>25 days</em> after irradiation: The ratio of tumour to host cells was determined by flow cytometry; the numerical density of tumour cells was obtained by stereological analysis of histological slides; the clonogenic fraction of tumour cells was assayed by plating an appropriate number of tumour cells and scoring the colonies; tumour volume was assessed by measuring two tumour diameters at right angles to each other. All parameters investigated, except tumour volume, undergo drastic changes during the first <em>2 weeks</em> after irradiation. From the directly measured parameters the following values and their variation with time could be derived. The number of host cells per tumour increased by a factor of <em>10</em> within the first <em>10 days</em> after irradiation, probably due to infiltration by blood-borne host cells. During the same time interval, the number of tumour cells decreased by a factor of <em>5</em>, whereas the total number of cells per tumour showed an increase by a factor of <em>4</em>. Since the host cells are considerably smaller than the tumour cells, the cellular numerical density increased by a factor of <em>3</em>, but approached the control level by <em>Day 18</em> after irradiation. From the number of clonogenic and non-clonogenic tumour cells the kinetics of repopulation and depopulation was obtained. Repopulation of irradiated tumours by surviving tumour cells as well as removal of inactivated tumour cells began immediately after irradiation and proceeded with exponential kinetics. Repopulation occurred with a doubling time of <em>4.4 ± 0.3 days</em> whereas inactivated tumour cells disintegrated with a halving time of <em>3.5 ± 0.7 days</em>. There were no indications that proliferation of doomed cells contributed significantly to tumour growth after X-irradiation.</p></div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 4","pages":"Pages 375-386"},"PeriodicalIF":0.0,"publicationDate":"1981-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90245-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18320786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1981-04-01DOI: 10.1016/0014-2964(81)90251-6
N.M. Barfod
Cell-specific G1-inhibitory (chalone) activity has been extracted from old JB-1 ascites tumors and purified by means of G-15 Sephadex chromatography. Four peaks of activity were obtained, the amount of activity in each peak varying from batch to batch. The first eluting activity peak probably represents chalone activity present in an aggregated form. The latest eluting activity peak was totally unspecific and could be attributed to the presence of high amounts of salts. The two intermediary peaks of activity were investigated in more detail. It is shown that the first eluting activity peak of these two is due to the polyamine spermine complexed to a carrier. Although the spermine complex exhibits a certain degree of cell-specific inhibitory activity in vitro, it is totally inactive in vivo. The second eluting activity peak containing the main part of cell-specific G-inhibitory activity has been characterized as a small molecular weight (Mr300–600), ampholytic, hydrophobic, slightly acidic, and thiol-containing peptide active both in vitro and in vivo.
{"title":"Partial purification and characterization of a cell specific G1-inhibitor (chalone) from JB-1 ascites tumors","authors":"N.M. Barfod","doi":"10.1016/0014-2964(81)90251-6","DOIUrl":"10.1016/0014-2964(81)90251-6","url":null,"abstract":"<div><p>Cell-specific G<sub><em>1</em></sub>-inhibitory (chalone) activity has been extracted from old JB-<em>1</em> ascites tumors and purified by means of G-<em>15</em> Sephadex chromatography. Four peaks of activity were obtained, the amount of activity in each peak varying from batch to batch. The first eluting activity peak probably represents chalone activity present in an aggregated form. The latest eluting activity peak was totally unspecific and could be attributed to the presence of high amounts of salts. The two intermediary peaks of activity were investigated in more detail. It is shown that the first eluting activity peak of these two is due to the polyamine spermine complexed to a carrier. Although the spermine complex exhibits a certain degree of cell-specific inhibitory activity <em>in vitro</em>, it is totally inactive <em>in vivo</em>. The second eluting activity peak containing the main part of cell-specific G-inhibitory activity has been characterized as a small molecular weight (<em>M</em><sub><em>r</em></sub><em>300–600</em>), ampholytic, hydrophobic, slightly acidic, and thiol-containing peptide active both <em>in vitro</em> and <em>in vivo</em>.</p></div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 4","pages":"Pages 421-431"},"PeriodicalIF":0.0,"publicationDate":"1981-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90251-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17517136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1981-04-01DOI: 10.1016/0014-2964(81)90250-4
D. Taramelli , L. Romani , A. Bonmassar , A. Goldin , M.C. Fioretti
Novel transplantation antigens have been detected in a Moloney virus-induced LSTRA lymphoma of BALB/c origin (H-2d), or in a chemically-induced L5178Y lymphoma of DBA/2 origin, following treatment of tumor-bearing hosts with 5-(3,3′-dimethyl-1-triazeno-)-imidazole-4-carboxamide (DTIC), for 4–8 transplant generations. Marked cell-mediated cytotoxic responses against DTIC-treated LSTRA or L5178Y lines were found by primary in vivo and secondary in vitro sensitization of histocompatible mice. Moreover, preliminary data show that no obvious antigenic cross-reactivity can be found among DTIC-treated sublines derived from distinct parental lymphomas. To test whether DTIC lines would express variable levels of normal histocompatibility antigens, cytotoxic lymphocytes were generated in vitro against alloantigens of H-2 complex or sub-regions of it and tested against parental or DTIC-treated lymphomas in a short-term 51Cr-release assay. A cold-inhibition test was performed with LSTRA or 4 LSTRA/DTIC sublines. The results showed that little or no difference in the expression of H-2 antigens recognized by cytotoxic lymphocytes could be detected between parental and DTIC-treated sublines. Moreover, no foreign H-2 specificities of H-2b or H-2k haplotypes detectable by cytotoxic lymphocytes could have been found in L5178Y or L5178Y/DTIC lymphomas.
{"title":"Expression of normal histocompatibility antigens in murine lymphomas treated with 5-(3,3′-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) in vivo","authors":"D. Taramelli , L. Romani , A. Bonmassar , A. Goldin , M.C. Fioretti","doi":"10.1016/0014-2964(81)90250-4","DOIUrl":"10.1016/0014-2964(81)90250-4","url":null,"abstract":"<div><p>Novel transplantation antigens have been detected in a Moloney virus-induced LSTRA lymphoma of BALB/c origin (<em>H-2<sup>d</sup></em>), or in a chemically-induced <em>L5178Y</em> lymphoma of <em>DBA/2</em> origin, following treatment of tumor-bearing hosts with <em>5-(3,3</em>′-dimethyl-<em>1</em>-triazeno-)-imidazole-<em>4</em>-carboxamide (DTIC), for <em>4–8</em> transplant generations. Marked cell-mediated cytotoxic responses against DTIC-treated LSTRA or <em>L5178Y</em> lines were found by primary <em>in vivo</em> and secondary <em>in vitro</em> sensitization of histocompatible mice. Moreover, preliminary data show that no obvious antigenic cross-reactivity can be found among DTIC-treated sublines derived from distinct parental lymphomas. To test whether DTIC lines would express variable levels of normal histocompatibility antigens, cytotoxic lymphocytes were generated <em>in vitro</em> against alloantigens of <em>H-2</em> complex or sub-regions of it and tested against parental or DTIC-treated lymphomas in a short-term <em><sup>51</sup>Cr</em>-release assay. A cold-inhibition test was performed with LSTRA or <em>4</em> LSTRA/DTIC sublines. The results showed that little or no difference in the expression of <em>H-2</em> antigens recognized by cytotoxic lymphocytes could be detected between parental and DTIC-treated sublines. Moreover, no foreign <em>H-2</em> specificities of <em>H-2<sup>b</sup></em> or H-<em>2<sup>k</sup></em> haplotypes detectable by cytotoxic lymphocytes could have been found in <em>L5178Y</em> or <em>L5178Y</em>/DTIC lymphomas.</p></div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 4","pages":"Pages 411-420"},"PeriodicalIF":0.0,"publicationDate":"1981-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90250-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17236852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1981-04-01DOI: 10.1016/0014-2964(81)90249-8
P. Bentvelzen , F. Westenbrink , J.J. Broerse , M.J. Van Zwieten
Fifty-two rat mammary tumours were tested by radioimmunoassay for the presence of antigens related to the envelope glycoprotein gp52 and core protein p28 of the murine mammary tumour virus and found to be negative. The tumours assayed were from WAG/Rij (16 cases), BN/BiRij (16 cases) and Sprague—Dawley (20 cases) rats. Thirty of the rats had been irradiated with fast neutrons, 16 with X-rays, one had been implanted with a 17-β-oestradiol pellet and 5 were untreated. The tumours studied included 22 fibroadenomas, 2 adenomas, 19 adenocarcinomas, 4 sarcomas, 1 carcinosarcoma, and 4 of undetermined type.
{"title":"Absence of antigens related to murine mammary tumour virus polypeptides in rat mammary tumours","authors":"P. Bentvelzen , F. Westenbrink , J.J. Broerse , M.J. Van Zwieten","doi":"10.1016/0014-2964(81)90249-8","DOIUrl":"10.1016/0014-2964(81)90249-8","url":null,"abstract":"<div><p>Fifty-two rat mammary tumours were tested by radioimmunoassay for the presence of antigens related to the envelope glycoprotein gp<em>52</em> and core protein p<em>28</em> of the murine mammary tumour virus and found to be negative. The tumours assayed were from WAG/Rij (<em>16</em> cases), BN/BiRij (<em>16</em> cases) and Sprague—Dawley (<em>20</em> cases) rats. Thirty of the rats had been irradiated with fast neutrons, <em>16</em> with X-rays, one had been implanted with a <em>17</em>-β-oestradiol pellet and <em>5</em> were untreated. The tumours studied included <em>22</em> fibroadenomas, <em>2</em> adenomas, <em>19</em> adenocarcinomas, <em>4</em> sarcomas, <em>1</em> carcinosarcoma, and <em>4</em> of undetermined type.</p></div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 4","pages":"Pages 407-410"},"PeriodicalIF":0.0,"publicationDate":"1981-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90249-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17335928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}